Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:17 AM
Ignite Modification Date:
2025-12-25 @ 4:17 AM
NCT ID:
NCT04066920
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed PCNSL of CD20+ diffuse large B cell lymphoma (DLBCL)
* PCNSL relapsed or refractory after frontline methotrexate-based chemotherapy (with or without radiation therapy)
* At least one measurable lesion, which is defined as longest diameter of lesion \> 0.5 cm, by contrast-enhanced MRI
* ECOG performance status 0-2
* Normal function of major organs
Exclusion Criteria:
* PCNSL other than DLBCL
* Primary ocular lymphoma
* PCNSL accompanied by systemic involvement
* Active infection with hepatitis B or C virus
* Known history of human immunodeficiency virus (HIV) infection
* Therapy with myelosuppressive chemotherapy or biologic therapy \< 21 days prior to registration
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
79 Years
Study:
NCT04066920
Study Brief:
Protocol Section:
NCT04066920